Referenties
De informatie die is gebruikt voor het maken van het hoofdstuk over PPMS
1. Rosati, G. (2001). The prevalence of multiple sclerosis in the world: an update.Neurological sciences, 22(2), 117-139.
2. Firth, D. (1941). The Case of Augustus d'Este (1794-1848): The First Account of Disseminated Sclerosis:(Section of the History of Medicine). Proceedings of the Royal Society of Medicine, 34(7), 381.
3. Murray, T. (2004). Multiple sclerosis: the history of a disease. Demos medical publishing.
4. Cottrell, D. A., Kremenchutzky, M., Rice, G. P. A., Koopman, W. J., Hader, W., Baskerville, J., & Ebers, G. C. (1999). The natural history of multiple sclerosis: a geographically based study 5. The clinical features and natural history of primary progressive multiple sclerosis. Brain, 122(4), 625-639.
5. Trojano, M., Lucchese, G., Graziano, G., Taylor, B. V., Simpson Jr, S., Lepore, V., ... & Butzkueven, H. (2012). Geographical variations in sex ratio trends over time in multiple sclerosis. PLOS one, 7(10), e48078.
6. Stys, P. K., Zamponi, G. W., van Minnen, J., & Geurts, J. J. (2012). Will the real multiple sclerosis please stand up?. Nature Reviews Neuroscience, 13(7), 507-514.
7. McFarland, H. F., & Martin, R. (2007). Multiple sclerosis: a complicated picture of autoimmunity. Nature immunology, 8(9), 913-919.
8. Steinman, L., Martin, R., Bernard, C., Conlon, P., & Oksenberg, J. R. (2002). MULTIPLE SCLEROSIS: Deeper Understanding of Its Pathogenesis Reveals New Targets for Therapy*. Annual review of neuroscience, 25(1), 491-505.
9. Trapp, B. D., & Nave, K. A. (2008). Multiple sclerosis: an immune or neurodegenerative disorder?. Annu. Rev. Neurosci., 31, 247-269.
10. Stadelmann, C., Albert, M., Wegner, C., & Brück, W. (2008). Cortical pathology in multiple sclerosis. Current opinion in neurology, 21(3), 229-234.
11. Miller, D. H. (2004). Biomarkers and surrogate outcomes in neurodegenerative disease: lessons from multiple sclerosis. NeuroRx, 1(2), 284-294.
12. Katz, D., Taubenberger, J. K., Cannella, B., McFarlin, D. E., Raine, C. S., & McFarland, H. F. (1993). Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis. Annals of neurology, 34(5), 661-669.
13. Brück, W., Bitsch, A., Kolenda, H., Brück, Y., Stiefel, M., & Lassmann, H. (1997). Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology. Annals of neurology, 42(5), 783-793.
14. Revesz, T., Kidd, D., Thompson, A. J., Barnard, R. O., & McDonald, W. I. (1994). A comparison of the pathology of primary and secondary progressive multiple sclerosis. Brain, 117(4), 759-765.
15. Thompson, A. J., Kermode, A. G., MacManus, D. G., Kendall, B. E., Kingsley, D. P., Moseley, I. F., & McDonald, W. I. (1990). Patterns of disease activity in multiple sclerosis: clinical and magnetic resonance imaging study. BMJ: British Medical Journal, 300(6725), 631.
16. Kalkers, N. F., Bergers, E., Castelijns, J. A., Van Walderveen, M. A. A., Bot, J. C. J., Ader, H. J., & Barkhof, F. (2001). Optimizing the association between disability and biological markers in MS. Neurology, 57(7), 1253-1258.
17. Fu, L., Matthews, P. M., De Stefano, N., Worsley, K. J., Narayanan, S., Francis, G. S., ... & Arnold, D. L. (1998). Imaging axonal damage of normal-appearing white matter in multiple sclerosis. Brain, 121(1), 103-113.
18. Bjartmar, C., Kidd, G., Mörk, S., Rudick, R., & Trapp, B. D. (2000). Neurological disability correlates with spinal cord axonal loss and reduced N‐acetyl aspartate in chronic multiple sclerosis patients. Annals of neurology,48(6), 893-901.
19. Petzold, A. (2005). Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss. Journal of the neurological sciences, 233(1), 183-198.
20. Miller, D. H., & Leary, S. M. (2007). Primary-progressive multiple sclerosis.The Lancet Neurology, 6(10), 903-912.
21. Ruet, A., Deloire, M., Charré-Morin, J., Hamel, D., & Brochet, B. (2013). Cognitive impairment differs between primary progressive and relapsing-remitting MS. Neurology, 80(16), 1501-1508.
22. Thompson, A. J., Montalban, X., Barkhof, F., Brochet, B., Filippi, M., Miller, D. H., & McDonald, W. I. (2000). Diagnostic criteria for primary progressive multiple sclerosis: a position paper. Annals of neurology, 47(6), 831-835.
23. Sellebjerg F, Barnes D, Filippini G, et al. EFNS guideline on treatment of multiple sclerosis relapses: report of an EFNS task force on treatment of multiple sclerosis relapses. Eur J Neurol 2005; 12: 939-46.
24. Leary SM, Miller DH, Stevenson VL, et al. Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial. Neurology 2003; 60: 44–51.
25. Leary SM, Thompson AJ. Primary progressive multiple sclerosis: current and future treatment options. CNS Drugs 2005; 19: 369–76.
26. Wolinsky JS, Narayana PA, O’Connor P, et al. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol 2007; 61: 14–24.
27. Koch M, de Keyser J. Irreversible neurological worsening following high-dose corticosteroids in advanced progressive multiple sclerosis. Clin Neuropharmacol 2006; 29: 18–19.
28. Novotna A, Mares J, Ratcliffe S, et al. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®) ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol. 2011 Sep;18(9):1122-31.
29. Okuda, D.T.. Immunosuppressive treatments in multiple sclerosis. Handb Clin Neurol. 2014;122:503-11.